H.C. Wainwright Reiterates Buy Rating on Aclaris Therapeutis (ACRS)

April 15, 2026 7:21 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $16.00 price target on Aclaris Therapeutis (NASDAQ: ACRS).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found